Use of TCR antibody fusion proteins as bispecific agents for NK and T cell-mediated immunotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Heidelberg, Universität Heidelberg, Dissertation, 2022
- Schlagwort
-
Proteine
Peptide
T-Lymphozyten-Rezeptor
- Ereignis
-
Veröffentlichung
- (wo)
-
Heidelberg
- (wer)
-
Universitätsbibliothek Heidelberg
- (wann)
-
2023
- Urheber
- Beteiligte Personen und Organisationen
- DOI
-
10.11588/heidok.00033201
- URN
-
urn:nbn:de:bsz:16-heidok-332012
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:56 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Teschner, Annkathrin
- Umansky, Viktor
- Universitätsbibliothek Heidelberg
Entstanden
- 2023
Ähnliche Objekte (12)
Next-Generation TCR-transgenic T cells for Immunotherapy
RNAi-mediated knockdown of the endogenous TCR improves safety of immunotherapy with TCR gene-modified T cells
Unleashing the power of NK cells in anticancer immunotherapy
Combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy
Mechanism and efficacy of a GD2-specific immunotherapy using NK cells
TcR
Characterization of a murine TCR specific for HLA-A2.1 restricted non-mutated MDM2 peptide for cancer immunotherapy
Ko-Tests: TCR
Editorial: NK-Myeloid Cell Interactions in the Tumor Microenvironment: Implications for Cancer Immunotherapy
IL-15-based trifunctional antibody-fusion proteins with costimulatory TNF-superfamily ligands for cancer immunotherapy
Towards antibody-mediated targeting of dendritic cells for cancer immunotherapy with multivalent polymer-antigen conjugates
Towards antibody-mediated targeting of dendritic cells for cancer immunotherapy with multivalent polymer-antigen conjugates
Next-Generation TCR-transgenic T cells for Immunotherapy
RNAi-mediated knockdown of the endogenous TCR improves safety of immunotherapy with TCR gene-modified T cells
Unleashing the power of NK cells in anticancer immunotherapy
Combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy
Mechanism and efficacy of a GD2-specific immunotherapy using NK cells
TcR
Characterization of a murine TCR specific for HLA-A2.1 restricted non-mutated MDM2 peptide for cancer immunotherapy
Ko-Tests: TCR
Editorial: NK-Myeloid Cell Interactions in the Tumor Microenvironment: Implications for Cancer Immunotherapy
IL-15-based trifunctional antibody-fusion proteins with costimulatory TNF-superfamily ligands for cancer immunotherapy
Towards antibody-mediated targeting of dendritic cells for cancer immunotherapy with multivalent polymer-antigen conjugates
Towards antibody-mediated targeting of dendritic cells for cancer immunotherapy with multivalent polymer-antigen conjugates
Next-Generation TCR-transgenic T cells for Immunotherapy
RNAi-mediated knockdown of the endogenous TCR improves safety of immunotherapy with TCR gene-modified T cells
Unleashing the power of NK cells in anticancer immunotherapy
Combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy
Mechanism and efficacy of a GD2-specific immunotherapy using NK cells
TcR
Characterization of a murine TCR specific for HLA-A2.1 restricted non-mutated MDM2 peptide for cancer immunotherapy
Ko-Tests: TCR
Editorial: NK-Myeloid Cell Interactions in the Tumor Microenvironment: Implications for Cancer Immunotherapy
IL-15-based trifunctional antibody-fusion proteins with costimulatory TNF-superfamily ligands for cancer immunotherapy
Towards antibody-mediated targeting of dendritic cells for cancer immunotherapy with multivalent polymer-antigen conjugates